Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. - Test2 - elhamkhani - TriplyDB

Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.

Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.

http://www.wikidata.org/entity/Q37109677

about

Advances in norovirus biology Norovirus immunology: Of mice and mechanisms Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.Vaccine against norovirus.Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.Norovirus in healthcare settings.Epidemiology of human noroviruses and updates on vaccine development A Gnotobiotic Pig Model for Determining Human Norovirus Inactivation by High-Pressure Processing High Protective Efficacy of Probiotics and Rice Bran against Human Norovirus Infection and Diarrhea in Gnotobiotic Pigs.Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives Enterobacter cloacae inhibits human norovirus infectivity in gnotobiotic pigs.Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency.The molecular pathology of noroviruses.Large animal models for vaccine development and testing.Order of aging of major human organs or systems and evaluation of health status based on aging.Prevalence of Human Parainfluenza Viruses and Noroviruses Genomes on Office Fomites.Experimental miniature piglet model for the infection of human norovirus GII.

P2860

Q27016152-0BB3E1DA-DABA-4F6B-9B01-389F3DB53C48 Q28083087-38F19625-1EDC-47FB-A3CE-68EA4A60A0B5 Q30248992-33956597-40B0-4D55-AFEB-67E6D6200D97 Q33578075-D6135DE0-AC63-4B9C-9446-32BE3E6571E4 Q34059360-51F99854-6FE4-42B3-AB36-A97B87544E60 Q34059409-58ED5B1C-D548-45FA-A168-B0AD6CD84E7C Q34134280-56CCD5E6-DACA-4F9D-8325-1CF69F23F865 Q34385139-E0196E94-C256-4CB7-A5D6-6AC93EEB375E Q36033161-9FDEF5FB-F59C-4510-BCCA-21A26EA701DA Q36194784-64085FC1-97B8-4840-9C49-66F02340CB96 Q36275589-454DDD50-546F-4F34-8552-D09BF1459ADF Q36835594-74D8513D-0C5B-4CCB-BD0B-887FAC3CDA6A Q36841045-09A294A5-A391-46DE-92E4-70C1C2E4EC85 Q38259875-286CC1D9-091B-4922-A608-2B59E5788E2E Q38492768-BD39B75C-6866-40DC-BA46-2ED525ABB4AD Q39228418-D04B691B-3C2F-47C5-AC3D-893577EAD54E Q47381155-D763C000-F05A-4953-AF2D-7363CDC506C6 Q47589746-B9ED586B-5A35-4678-ABFF-E204749D75E1

P2860

Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.

http://www.wikidata.org/entity/Q37109677

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Median infectious dose of huma ...... reatment and increased by age.

@en

Median infectious dose of huma ...... reatment and increased by age.

@nl

type

label

Median infectious dose of huma ...... reatment and increased by age.

@en

Median infectious dose of huma ...... reatment and increased by age.

@nl

prefLabel

Median infectious dose of huma ...... reatment and increased by age.

@en

Median infectious dose of huma ...... reatment and increased by age.

@nl

P1433

Q37109677-16315F13-8F3A-480F-8D8D-7E51F7BE485F

P1476

Q37109677-E6C45C2C-5B8D-4BCB-869A-A2BA24E3F7F9

P2093

Q37109677-12C94113-FA4F-42F4-8566-D50DEB07760A

Q37109677-39376978-7F17-404A-B798-C3785A011893

Q37109677-488083BE-A558-4753-9D0F-386FBDA2C041

Q37109677-571F7837-3732-4A1D-A036-2D936790024B

Q37109677-62EC6DC4-570C-4B26-B59E-19C08154C6A0

Q37109677-7AAB315C-F131-42DA-ADE0-79A4C8F69E9E

Q37109677-9BB128EB-3C96-4C61-B577-B1938A0D2D5D

Q37109677-A21B4CEB-A38C-4758-B890-3A6555137EE8

Q37109677-C2739111-C205-4954-9295-5EFC2174C7A1

Q37109677-D52DCF1C-AB86-4F12-9ED8-E7CA2974232C

P2860

Q37109677-0B829D60-6AB9-4CCE-A7A4-E7F8FDF4A6B6

Q37109677-103ED904-F266-4128-A491-314568F76568

Q37109677-13BBD53D-AAF9-4EA5-BE4B-D5F8CCB652A1

Q37109677-1B507F11-3FFA-42BE-A272-B313A18B4061

Q37109677-1CD306CE-67D3-45ED-850E-C5D3678BA434

Q37109677-1D0BABEB-F924-4C33-AA90-6FDDD885BFA5

Q37109677-1FC997DD-B00A-4C6A-B5AE-06A7F0FB8818

Q37109677-23C383F9-E560-469C-B66C-A7DB267FBD75

Q37109677-2FFA1B58-087B-4A82-A77A-6237EEB5ECEB

Q37109677-30245828-3A53-4388-BF2A-7FFEBB765938

P304

Q37109677-1298D659-FE84-4067-B992-63AD448A5A5E

P31

Q37109677-111CE027-046D-408F-A396-912485436233

P356

Q37109677-683139B0-B2DF-4762-8D75-C6C6B3CD04DD

P407

Q37109677-1F9CD9C4-4520-4451-AA24-940EB1167519

P433

Q37109677-048F9000-60CD-437F-A84D-E65FCD89025B

P478

Q37109677-1789B63C-92B5-470C-85C7-711C1C2FB769

P50

Q37109677-172DAA5D-7C6D-452A-B5FE-F39F7EBC713D

Q37109677-DF42AFC4-38D7-464A-B791-E6F3CF139384

P577

Q37109677-C734540F-F9DA-4EC0-AD7D-E3FCD86526E5

P5875

Q37109677-01E19CE7-2BB3-4378-A524-FF490E9A13B6

P698

Q37109677-C5840D3D-DF5E-4398-905D-31F684B91D9A

P921

Q37109677-0D5BE4C0-A706-406F-AD6B-E21AD63C5916

P932

Q37109677-5F7194D9-E4AD-4F43-9BB4-8F4995655136

P356

P1433

Journal of General Virology

P1476

Median infectious dose of huma ...... reatment and increased by age.

@en

P2093

Fangning Liu

http://www.w3.org/2001/XMLSchema#string

Guohua Li

http://www.w3.org/2001/XMLSchema#string

Jacob Kocher

http://www.w3.org/2001/XMLSchema#string

Ke Wen

http://www.w3.org/2001/XMLSchema#string

Ming Tan

http://www.w3.org/2001/XMLSchema#string

Ming Xia

http://www.w3.org/2001/XMLSchema#string

Tammy Bui

http://www.w3.org/2001/XMLSchema#string

Weiming Zhong

http://www.w3.org/2001/XMLSchema#string

Xi Jiang

http://www.w3.org/2001/XMLSchema#string

Xingdong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Norwalk virus shedding after experimental human infection

Cellular and humoral immunity following Snow Mountain virus challenge

Asymptomatic and symptomatic excretion of noroviruses during a hospital outbreak of gastroenteritis

Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge

Genetic diversity among sapoviruses

Pathogenesis of noroviruses, emerging RNA viruses

Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle.

PROCUREMENT AND MAINTENANCE OF GERM-FREE SEINE FOR MICROBIOLOGICAL INVESTIGATIONS.

Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns.

A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.

P304

2005-2016

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1099/VIR.0.054080-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 9

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242333898

http://www.w3.org/2001/XMLSchema#string

P698

23804568

http://www.w3.org/2001/XMLSchema#string

P921

P932

3749057

http://www.w3.org/2001/XMLSchema#string